Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe site revision label changed from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoChange DetectedDeleted the 403 Forbidden error page content, including the HTML snippet and the Home link. The visible error notice on the study detail page is removed, leaving the standard page chrome and navigation.SummaryDifference0.5%

- Check25 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study content with an error message. The visible area shows the site's generic header and footer, indicating the record is inaccessible.SummaryDifference19%

- Check32 days agoChange DetectedThe page now shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This update reflects an upgrade to the site's content-management/template system rather than changes to the study details.SummaryDifference0.0%

- Check39 days agoChange DetectedResults for the FLX475 dose-escalation study were posted (2026-09-03), and the page now links the Study Protocol (2022-09-01) and the Statistical Analysis Plan (2023-06-09). The record also documents the results submission history (e.g., Results First Submitted/Posted) and related documents provided by the sponsor.SummaryDifference2%

- Check46 days agoChange DetectedThe page revision tag was updated from v3.6.5 to v3.6.6, representing a minor metadata update to the page version.SummaryDifference0.0%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.